Alembic Pharmaceuticals Faces Profit Decline Amidst Financial Evaluation Adjustments

Alembic Pharmaceuticals has recently undergone an evaluation adjustment, reflecting changes in its underlying financial metrics and market position. The stock's technical trend has shifted to a sideways movement, indicating a lack of clear price momentum. This adjustment comes in light of various performance indicators, including a notable decline in operating profit growth over the past five years, which has averaged -7.30%.
In the most recent quarter, the company reported a decrease in profit after tax, falling to Rs 156.89 crore, a drop of 12%. Additionally, the operating profit to interest ratio reached its lowest point at 11.09 times, while the debt-equity ratio stood at 0.24 times, marking a significant level of leverage. Despite these challenges, Alembic Pharmaceuticals maintains a strong ability to service its debt, evidenced by a low debt to EBITDA ratio of 0.67 times.

The stock has generated a return of 3.95% over the past year, contrasting with a backdrop of declining profits. Furthermore, Alembic Pharmaceuticals is trading at a discount compared to its peers' average historical valuations, with a return on capital employed (ROCE) of 11.5 and an enterprise value to capital employed ratio of 3.2.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.